Omeros (OMER) EBT (2010 - 2026)
Omeros (OMER) posted EBT of $51.3 million for Q1 2026, up 247.46% sequentially from -$34.8 million in Q4 2025, and up 236.58% YoY from $15.2 million in Q1 2025.
Omeros (OMER) EBT (2010 - 2026) Analysis & Trends
Omeros has reported EBT for 17 years, with the latest figure at $51.3 million in Q1 2026.
- Quarterly EBT rose 236.58% year-over-year to $51.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$74.9 million (up 56.96% YoY) and the FY2025 annual result came in at -$2.8 million, up 98.45% from the prior year.
- EBT climbed to $51.3 million in Q1 2026 per OMER's latest filing, from -$34.8 million in the prior quarter.
- Over five years, EBT peaked at $51.3 million in Q1 2026 and troughed at -$65.1 million in Q2 2024.
- A 5-year average of -$38.3 million and a median of -$41.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2026: EBT tumbled 141.34% in 2022, then surged 236.58% in 2026.
- Over 5 years, EBT stood at -$27.6 million in 2022, then slumped by 111.24% to -$58.3 million in 2023, then jumped by 44.97% to -$32.1 million in 2024, then dropped by 8.41% to -$34.8 million in 2025, then surged by 247.46% to $51.3 million in 2026.
- According to Business Quant data, EBT over the past three periods registered $51.3 million, -$34.8 million, and -$47.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 6.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.67 Mn |
| Mar 31, 2026 | 51.31 Mn |
| Dec 31, 2025 | -34.79 Mn |
| Sep 30, 2025 | -47.43 Mn |
| Jun 30, 2025 | -43.98 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -32.09 Mn |
| Sep 30, 2024 | -39.23 Mn |
| Jun 30, 2024 | -65.13 Mn |
| Mar 31, 2024 | -43.85 Mn |
| Dec 31, 2023 | -58.32 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -44.29 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -27.61 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -41.70 Mn |
| Mar 31, 2022 | -40.52 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -22.70 Mn |